Lilly shares safety, tolerability data on its next-gen obesity drug
Number of participants who experienced cardiac events were too small to draw meaningful conclusions, experts said
Adobe
By Elaine Chen
June 6, 2026
National Biotech Reporter
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Eli Lilly has already established that its next-generation obesity drug can lead to highly rapid weight loss. Researchers disclosed new data Saturday that provide more details on the safety and tolerability of the closely-watched therapy.
Lilly previously said that in one late-stage study, called TRANSCEND-T2D-1, retatrutide helped people with diabetes lower blood sugar and lose a significant amount of weight, which is notable since those who have diabetes tend to lose less weight on treatment than those who don’t.
Advertisement
New data showed that seven out of the 403 participants who received retatrutide experienced arrhythmias (irregular heart beats), and three treated participants experienced major cardiovascular complications, compared with none in the placebo group. The data were presented at the annual meeting of the American Diabetes Association and published in the Lancet.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
Monthly
$39
Totals $468 per year
Totals $468 per year
Starter
$30
for 3 months, then $399/year
Then $399/year
Annual
$399
Save 15%
Save 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A Quote
Savings start at 25%!
2-10 Users
$300
Annually per user
$300 Annually per user
To read the rest of this story subscribe to STAT+.
biotechnology, chronic disease, diabetes, drug development, Obesity, Pharmaceuticals, STAT+
Submit a correction request Reprints
National Biotech Reporter
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Newsletter
Stay on top of the latest developments coming out of the American Diabetes Association conference.
Please enter a valid email address.Sign Up
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise
What stripping civil service protections for thousands of federal workers will mean for HHS
Senior NIH official pushes MAHA strategy to skeptical ADA audience
Tiny HHS office tasked with protecting research participants’ safety is running on fumes
\
2025 Edition: Ranking Biotech’s Top Venture Capital Firms
\
\
STAT@ASCO: Science vs. Cancer\
\
Chicago, IL May 29 
\
\
ASCO 2026: The STAT Recap\
\
Virtual Jun 3 
\
\
2026 Breakthrough Summit West\
\
San Francisco, CA May 19
Revolution Medicines starts shipping experimental pancreatic cancer drug
For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
What stripping civil service protections for thousands of federal workers will mean for HHS
Drug companies, patient groups urge FDA to pause commissioner’s voucher program
Practice-changing results reported for Revolution Medicines pancreatic cancer drug
Recommended
Pharma
PharmaJune 6, 2026
STAT Plus: Detailed data show Pfizer’s monthly obesity drug continues to show potential
The Readout
The ReadoutJune 5, 2026
STAT Plus: Will Makary’s FDA voucher program survive?
Politics
PoliticsJune 4, 2026
STAT Plus: Drug companies, patient groups urge FDA to pause commissioner’s voucher program
Pharma
PharmaJune 4, 2026
STAT Plus: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial
The Readout
The ReadoutJune 4, 2026